Rose-Jones Lisa J, Mclaughlin Vallerie V
UNC Center for Heart & Vascular Care, 160 Dental Circle, CB 7075, Chapel Hill, NC 27599-7075, USA.
Curr Cardiol Rev. 2015;11(1):73-9. doi: 10.2174/1573403x09666131117164122.
Pulmonary arterial hypertension (PAH) is a panvasculopathy that affects the distal pulmonary arteries and leads to restricted blood flow. This increased afterload leads to adaptive mechanisms of the right ventricle, with eventual failure once it can no longer compensate. Pulmonary hypertension from associated conditions, most importantly left heart disease, i.e. heart failure, can also lead to the same sequela. Patients often experience early vague symptoms of dyspnea and exercise intolerance, and thus PH can elude clinicians until right heart failure symptoms predominate. Evidence-based treatment options with pulmonary vasodilators are available for those with PAH and should be employed early. It is essential that patients be accurately categorized by their etiology of PH, as treatment strategies differ, and can potentially be dangerous if employed in the wrong clinical scenario.
肺动脉高压(PAH)是一种影响远端肺动脉的广泛性血管病变,可导致血流受限。这种后负荷增加会引发右心室的适应性机制,一旦右心室无法再代偿,最终就会导致衰竭。相关疾病引起的肺动脉高压,最重要的是左心疾病,即心力衰竭,也可导致相同的后果。患者通常早期会出现呼吸困难和运动不耐受等模糊症状,因此在右心衰竭症状占主导之前,肺动脉高压可能会被临床医生忽视。对于患有PAH的患者,有基于证据的肺血管扩张剂治疗方案可供使用,应尽早采用。必须根据患者肺动脉高压的病因进行准确分类,因为治疗策略不同,如果在错误的临床情况下使用可能会有潜在危险。